Recursion will report its fourth quarter and full year 2025 financial results before markets open on February 25 at 8:00 am ET, followed by a (L)earnings call livestreamed on its social channels. Investors can submit questions in advance via the company’s web form to engage with management during the session.

Shares of Recursion Pharmaceuticals fell on February 18 as broader technology stocks retreated after concerns around Nvidia’s outlook triggered sector-wide selling pressure. The pullback highlights investor sensitivity to developments in AI hardware providers and potential knock-on effects for tech-focused biotech firms.